Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for KB408 in Severe alpha-1 antitrypsin deficiency. The expected timing is based on the latest available company guidance and may change.
SERPENTINE-1 study. 2/24- Dosed first patient. 12/12/24- Safety data reported. 5/6/25- Molecular results from cohort 2 & 3 by YE 2025. 11/03/25:- Ongoing enrollment; interim Cohort 2B data in H1 2026. 02/17/26:- SERPENTINE-1 Cohort 2B enrollment ongoing; interim repeat-dose KB408 data now expected in 2026. 05/04/26:- SERPENTINE-1 Cohort 2B enrollment ongoing; still expect interim repeat-dose KB408 data in 2026. 08/03/26:- SERPENTINE-1 Cohort 2B enrollment continues; interim results now expected in 2027.
Verification
Confirm timing and program details against the company announcement or filing.